Explore the latest advancements in denosumab biosimilars, enhancing treatment options for osteoporosis and bone metastases in ...
Biosimilar development costs could plummet from $100 million to $5 million, enabling smaller companies to enter the market ...
In 2025, the latest biosimilar policy developments included bipartisan efforts to enhance affordability and reduce barriers ...
Discover the top 5 regulatory biosimilar news of 2025, highlighting FDA approvals that enhance treatment options and ...
Tyruko, the first natalizumab biosimilar for multiple sclerosis, promises significant savings and competition in the US market.
Biosimilar developers achieve key European approvals for denosumab and golimumab, enhancing patient access while facing US market entry delays.
A retrospective observational study found no significant differences in progression-free survival or safety in patients with colorectal cancers in Japan treated with ABP 215, Amgen’s bevacizumab ...
April E. Weisbruch is a partner at McDermott, Will, & Emery LLP. She focuses her practice on intellectual property (IP) matters, particularly in managing large-scale IP litigation and counseling. She ...
FDA's new guidance clarifies promotional practices for biosimilars, ensuring accurate marketing and preventing misleading ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback